Tag: Impella 2.5


How Dr. Tony DeMartini Chooses Between Impella 2.5® vs Impella CP® for Protected PCI

In this Q&A session, Dr. Tony DeMartini describes his decision-making behind choosing the Impella 2.5 vs the Impella CP device in Protected PCI. Overall, Dr. DeMartini briefly discusses the several patient variables which help him decide between the two Impella devices. Related Content: Chadi Alraies, MD, Presents Case of an Elderly Patient with Severe Aortic … Continue reading “How Dr. Tony DeMartini Chooses Between Impella 2.5® vs Impella CP® for Protected PCI”

Impella 2.5 Support in an Octogenarian Patient with Ostial Left Main Stenosis

Dr. Michael Amponsah presents a case of an 86-year-old female patient with non-ST elevation acute coronary syndrome at time of emergency department admission. The patient described in this case study also had a medical history of hypertension, hyperlipidemia, and hypothyroidism. After discussing treatment options, the patient declined coronary artery bypass grafting surgery. Dr. Amponsah describes … Continue reading “Impella 2.5 Support in an Octogenarian Patient with Ostial Left Main Stenosis”

Specialist Opinion: Dr. Perwaiz Meraj

Dr. Perwaiz Meraj of Northwell Health discusses a new study demonstrating potential survival with Impella 2.5® heart pump insertion pre-PCI in heart attacks involving the left main coronary artery. IM2-049-17

IABP vs Impella®: Incidence of Bleeding and Vascular Complications

Key Takeaways Patients undergoing high-risk PCI often require additional hemodynamic support, particularly with the help of ventricular assist devices. There is no significant difference between Impella 2.5® and IABP in terms of bleeding risk and vascular complications. High-risk patients with acute coronary syndrome (ACS) often require additional cardiac support during a protected percutaneous coronary intervention … Continue reading “IABP vs Impella®: Incidence of Bleeding and Vascular Complications”

Impella 2.5™ and VA-ECMO Provide Hemodynamic Improvement in Patients with Cardiogenic Shock

Standard treatment of cardiogenic shock often includes the initiation of revascularization and the use of vasoconstrictors, inotropes, and the intra-aortic balloon pump. When cardiogenic shock resists traditional therapy, it can present a clinical challenge in addition to a substantially high mortality rate. Despite the advances in medicine and technology, cardiogenic shock maintains a mortality rate of a little less than 50%.1Current options for refractory cardiogenic shock have grown to include not only the armamentarium of standard cardiogenic shock therapies, but also percutaneous mechanical circulatory support (MCS) devices like the Impella 2.5™. Additionally, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is often considered for patients with refractory cardiogenic shock, sometimes in combination with MCS devices, to help improve hemodynamic support. Continue readingImpella 2.5™ and VA-ECMO Provide Hemodynamic Improvement in Patients with Cardiogenic Shock

Women With Cardiogenic Shock Derive Greater Benefit From Impella 2.5

The aim of this recent cVAD Registry analysis was to assess survival differences between men and women supported with Impella 2.5 in the setting of acute myocardial infarction (AMI) complicated by cardiogenic shock (CS). The article concludes that early initiation of hemodynamic support prior to PCI with Impella 2.5, in the setting of AMI complicated by CS, was associated with a greater survival benefit to hospital discharge in women compared to men. This despite a higher predicted risk of mortality and a greater revascularization failure rate for women.
Continue readingWomen With Cardiogenic Shock Derive Greater Benefit From Impella 2.5

Protected PCI Programs: Training with the Impella 2.5™ Heart Pump

Training and education are key components of Protected PCI™ programs using the Impella 2.5™ heart pump.Who Should Be Trained?Successful Protected PCI programs aim to train everyone involved in the Protected PCI program and include:
  • Cardiovascular surgery staff
  • Perfusion staff
  • Cardiovascular nurses and technologists from the cath lab who assist with the set-up and insertion of the Impella 2.5 device
  • Critical care nurses who care for the patient, monitor the device, change tubing and troubleshoot alarms
  • ICU staff who accommodate the acute needs of Protected PCI patients, troubleshoot alarms, titrate drips and fulfill charting requirements
  • Pharmacists who develop heparin drip protocols for the Impella 2.5 device, provide dextrose solution to the cath lab and handle orders for pre- and post-procedure care
  • Clinical Nurse Navigators who provide education and follow-up for patients
  • Coding and billing for reimbursement codes for the insertion, care and removal of the Impella 2.5 device
  • Clinical Nurse Educators who establish training and competency-based evaluation
Continue readingProtected PCI Programs: Training with the Impella 2.5™ Heart Pump